Programmable CRISPR tools are turning stem cell biology into something closer to software engineering, shrinking ...

Rare diseases pose unique challenges in the medical field, often affecting a small but vulnerable population with limited treatment options. The Rare Disease Challenge (RaDiChal) is a groundbreaking ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

CRISPR's gene therapy, Casgevy, faces operational challenges and stiff competition from Lyfgenia, impacting its market adoption. The initial commercial rollout of gene therapies requires the ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

Researchers used CRISPR to change the number of chromosomes in Arabidopsis by fusing chromosome arms, reducing the genome ...

2023 was an important year for patients with sickle cell disease. Prior to CRISPR, the only cure for the life-long ailment was a bone marrow transplant, which is notoriously dangerous and costly. This ...

Scientists from Kolkata-based Bose Institute have created GlowCas9--a CRISPR protein that lights up while performing gene ...

A new genome editing technology known as CRISPR has the potential to revolutionize the way scientists study diseases and genetics. “I think it’s a really useful tool for science, in fact it’s sort of ...